Dupixent was approved for treating COPD with raised blood eosinophils in the EU in July 2024. Dupixent was also approved for the COPD indication in China last week. Sanofi’s stock has gained 16.0% so ...
The FDA has approved Dupixent (dupilumab) as an add-on therapy for adults with poorly controlled COPD, especially those with ...
The approval was supported by data from the 52-week, randomized, double-blind, multicenter, parallel-group, placebo-controlled, phase 3 trials BOREAS and NOTUS.
The US Food and Drug Administration has approved dupilumab as an add-on maintenance therapy for adults whose chronic ...
Regeneron (REGN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Evan ...
An individual doesn’t develop heart disease in one day. It develops over several months and years. Therefore, it is crucial ...
A team of doctors at CK Birla Hospital, Gurugram, successfully performed a complex surgery on a 34-year-old woman suffering ...
The FDA has approved Dupixent as an add-on maintenance treatment for adults with poorly controlled COPD and high counts of ...
Analyst Julian Harrison of BTIG maintained a Buy rating on Apogee Therapeutics, Inc. (APGE – Research Report), with a price target of ...
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for ...
Modalis Therapeutics has been awarded a rare paediatric disease designation by the US Food and Drug Administration (FDA) for ...
The man charged with attempting to assassinate Donald Trump after allegedly positioning himself with a rifle outside one of the former president’s Florida golf courses is due to appear in court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback